26204 Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study - 07/08/21
Doi : 10.1016/j.jaad.2021.06.379
Michael Migden, MD
University of Texas MD Anderson Cancer Center, Departments of Dermatology, Division of Internal Medicine, and Head and Neck Surgery, Division of Surgery, Houston, TX
Alexander Guminski, MD, PhD
Department of Oncology, Royal North Shore Hospital, St Leonards, Australia
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Mater Hospital, Sydney, Australia
Ralf Gutzmer, MD
Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hannover, Germany
Nicholas Squittieri, MD
Medical Affairs Oncology and Long Term Care, Sun Pharmaceutical Industries, Inc, Princeton, NJ
Peter Foley, MBBS, BMedSc, MD, FACD
Department of Dermatology, St Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia
The University of Melbourne, Parkville, Victoria, Australia
Skin Health Institute Inc, Carlton, Victoria, Australia
Il testo completo di questo articolo è disponibile in PDF.
| Commercial Disclosure: Medical writing and editorial support were provided by AlphaBioCom, LLC, and funded by Sun Pharmaceutical Industries, Inc. |
© 2021
Pubblicato da Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB89 - settembre 2021 Ritorno al numero
Articolo precedente
- 26202 Antineoplastic therapy after discontinuation of sonidegib 200 mg in patients with advanced basal cell carcinoma: Results from the 42-month, randomized, double-blind BOLT study
- Ralf Gutzmer, Alexander Guminski, Peter Foley, Anne Lynn S. Chang, Karl Lewis, Nicholas Squittieri, Carmen Loquai
- 26206 Effect of sonidegib on secondary tumor size endpoints through 12 weeks of treatment in patients with nevoid basal cell carcinoma syndrome
- John Lear, Axel Hauschild, Nicholas Squittieri, Nicole Basset-Seguin, Reinhard Dummer
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?